Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1547572 | 0.81 | SMN1; SMN2 (0.47) | SMN1; SMN2CA12CA1CA2CA4 | |
| SCHEMBL483653 | 0.80 | CA1 (0.55) | CA12CA1CA2CA4CA7 | |
| SCHEMBL25434306 | 0.77 | CA1 (0.61) | SMN1; SMN2CA12CA1CA2CA4 | |
| SCHEMBL151213 | 0.77 | CA1 (0.61) | SMN1; SMN2CA12CA1CA2CA4 | |
| SCHEMBL27753904 | 0.77 | CA1 (0.61) | SMN1; SMN2CA12CA1CA2CA4 | |
| SCHEMBL11397101 | 0.76 | SMN1; SMN2 (0.47) | SMN1; SMN2CA12CA1CA2CA4 | |
| Cyanide SCHEMBL31190156 | 0.75 | SMN1; SMN2 (0.54) | SMN1; SMN2CA12CA1CA2CA4 | |
| SCHEMBL1332133 | 0.75 | CYP3A4 (0.57) | SMN1; SMN2CA12CA1CA2CA4 | |
| SCHEMBL20533560 | 0.75 | SMN1; SMN2 (0.46) | SMN1; SMN2CA12CA1CA2CA4 | |
| SCHEMBL1706919 | 0.75 | APLNR (0.49) | SMN1; SMN2CA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230202980-A1 | N-(2-Aminophenyl)-Prop-2-Enamide Derivatives, and Uses Thereof in the Treatment of Cancer | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2023-06-29 | — | — | US | disclosed |
| EP-4021906-A1 | N-(2-AMINOPHENYL)-PROP-2-ENAMIDE DERIVATIVES, AND USES THEREOF IN THE TREATMENT OF CANCER | National University of Singapore (SG) | 2022-07-06 | — | — | EP | disclosed |
| WO-2021041861-A1 | N-(2-AMINOPHENYL)-PROP-2-ENAMIDE DERIVATIVES, AND USES THEREOF IN THE TREATMENT OF CANCER | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2021-03-04 | — | — | WO | disclosed |
| US-10662194-B2 | Substituted 6-anilino-9-heterocyclylpurine derivatives for inhibition of plant stress | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2020-05-26 | — | — | US | disclosed |
| US-20170342072-A1 | SUBSTITUTED 6-ANILINO-9-HETEROCYCLYLPURINE DERIVATIVES FOR INHIBITION OF PLANT STRESS | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2017-11-30 | — | — | US | disclosed |
| EP-3233860-A1 | SUBSTITUTED 6-ANILINO-9-HETEROCYCLYLPURINE DERIVATIVES FOR INHIBITION OF PLANT STRESS | Univerzita Palackého V Olomouci (CZ) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016095881-A1 | SUBSTITUTED 6-ANILINO-9-HETEROCYCLYLPURINE DERIVATIVES FOR INHIBITION OF PLANT STRESS | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2016-06-23 | — | — | WO | disclosed |
| US-20030199694-A1 | Thermally stable trimetrexates and processes for producing the same | MEDIMMUNE ONCOLOGY, INC. | 2003-10-23 | — | — | US | disclosed |
| US-20020107393-A1 | Tremextrexate derivatives and pharmaceutical compositions comprising the same | MEDIMMUNE ONCOLOGY, INC. | 2002-08-08 | — | — | US | disclosed |
| EP-1080079-A4 | THERMALLY STABLE TRIMETREXATES AND PROCESSES FOR PRODUCING THE SAME | US BIOSCIENCE (US) | 2001-10-04 | — | — | EP | disclosed |
| US-6258952-B1 | CRYSTALLIZATION | MEDIMMUNE ONCOLOGY, INC. | 2001-07-10 | — | — | US | disclosed |
| EP-1080079-A1 | THERMALLY STABLE TRIMETREXATES AND PROCESSES FOR PRODUCING THE SAME | U.S. BIOSCIENCE, INC. (US) | 2001-03-07 | — | — | EP | disclosed |
| US-6017922-A | Thermally stable trimetrexates and processes for producing the same | U.S. BIOSCIENCE, INC. (US) | 2000-01-25 | — | — | US | disclosed |
| WO-1999059981-A1 | THERMALLY STABLE TRIMETREXATES AND PROCESSES FOR PRODUCING THE SAME | U.S. BIOSCIENCE, INC. (US) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202980-A1 | N-(2-Aminophenyl)-Prop-2-Enamide Derivatives, and Uses Thereof in the Treatment of Cancer | SALL4, GLI2, GLI1 | SMN1; SMN2 612/4885CA12 2841/4885CA1 4028/4885 |
| US-10662194-B2 | Substituted 6-anilino-9-heterocyclylpurine derivatives for inhibition of plant stress | TPMT, MTAP, ATIC | SMN1; SMN2 4827/4885CA12 4071/4885CA1 3738/4885 |
| US-20170342072-A1 | SUBSTITUTED 6-ANILINO-9-HETEROCYCLYLPURINE DERIVATIVES FOR INHIBITION OF PLANT STRESS | TPMT, MTAP, ATIC | SMN1; SMN2 4827/4885CA12 4071/4885CA1 3738/4885 |
| US-20030199694-A1 | Thermally stable trimetrexates and processes for producing the same | TYMS, TYMP, TOP1 | SMN1; SMN2 1527/4885CA12 1651/4885CA1 1156/4885 |
| US-20020107393-A1 | Tremextrexate derivatives and pharmaceutical compositions comprising the same | TYMP, TYMS, DTYMK | SMN1; SMN2 1042/4885CA12 1704/4885CA1 2110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.